G1 THERAPEUTICS INC. - COMMON STOCK

G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023

22 فبراير 2023 09:00:17 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)

13 فبراير 2023 05:00:38 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 فبراير 2023 15:46:01 بحسب Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference

11 يناير 2023 06:00:47 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

09 يناير 2023 05:30:31 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023

04 يناير 2023 05:30:12 بحسب Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference

03 يناير 2023 13:00:27 بحسب Nasdaq GlobeNewswire

Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment

07 ديسمبر 2022 17:04:19 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 ديسمبر 2022 22:41:26 بحسب Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference

23 نوفمبر 2022 09:30:26 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Closing of Offering of Common Stock

22 نوفمبر 2022 15:01:04 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Pricing of Offering of Common Stock

17 نوفمبر 2022 19:12:26 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Proposed Public Offering of Common Stock

17 نوفمبر 2022 15:01:05 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights

02 نوفمبر 2022 05:30:33 بحسب Nasdaq GlobeNewswire

Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)

02 نوفمبر 2022 05:28:23 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 نوفمبر 2022 16:40:30 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer

26 أكتوبر 2022 08:26:34 بحسب Nasdaq GlobeNewswire

G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022

19 أكتوبر 2022 11:30:57 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)

10 أكتوبر 2022 05:30:06 بحسب Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 أكتوبر 2022 16:00:53 بحسب Nasdaq GlobeNewswire